Researchers looked at data from a previous trial involving 54 patients who received uncemented hip replacements. These patients were originally enrolled in a study testing two doses of denosumab compared to a placebo. The team analyzed bone density around the hip joint and other health measures at an average of 5.6 years after surgery.
The results showed no statistically significant difference between the drug group and the placebo group. Bone density in both the hip cup and the thigh bone declined gradually over time for everyone, regardless of treatment. Patients also reported similar levels of pain and function, and the rate of abnormal bone growth was the same in both groups.
Because this is a secondary analysis of a Phase 2 trial, the findings are limited. The study was not designed to answer questions about long-term bone preservation or clinical outcomes like the need for revision surgery. Readers should understand that this does not prove the drug is ineffective for all patients, but it shows no clear benefit for this specific group over five years.